BIOMAT Database Logo BIOMAT Database Logo

[Factors of nonspecific resistance in hepatitis B and acute hepatic insufficiency]. 1990

A G Rakhmanova, and T B Muradnazarova, and N F Amerikantseva, and T P Demidenko, and N V Badosova

Studies of nonspecific resistance factors in grave forms of viral hepatitis B (VHB) have revealed their significance in the prediction of acute hepatic insufficiency (AHI) development and its unfavorable outcome. IgM and IgA levels were found the most informative as far as the prognosis is concerned; these levels were the highest in the patients with precoma eventuating in hepatic coma. C3 complement concentration was reduced in all the patients whatever the disease severity, but more so in those developing AHI, which fact may serve the criterion predicting AHI development in VHB; to add to this, C3 complement level reflects the degree of hepatocyte destruction whereas the degree of transferrin level reduction is explained by its impaired synthesis by the liver as well. Transferrin levels were reduced in all the patients with AHI.

UI MeSH Term Description Entries
D007070 Immunoglobulin A Represents 15-20% of the human serum immunoglobulins, mostly as the 4-chain polymer in humans or dimer in other mammals. Secretory IgA (IMMUNOGLOBULIN A, SECRETORY) is the main immunoglobulin in secretions. IgA,IgA Antibody,IgA1,IgA2,Antibody, IgA
D007075 Immunoglobulin M A class of immunoglobulin bearing mu chains (IMMUNOGLOBULIN MU-CHAINS). IgM can fix COMPLEMENT. The name comes from its high molecular weight and originally was called a macroglobulin. Gamma Globulin, 19S,IgM,IgM Antibody,IgM1,IgM2,19S Gamma Globulin,Antibody, IgM
D007136 Immunoglobulins Multi-subunit proteins which function in IMMUNITY. They are produced by B LYMPHOCYTES from the IMMUNOGLOBULIN GENES. They are comprised of two heavy (IMMUNOGLOBULIN HEAVY CHAINS) and two light chains (IMMUNOGLOBULIN LIGHT CHAINS) with additional ancillary polypeptide chains depending on their isoforms. The variety of isoforms include monomeric or polymeric forms, and transmembrane forms (B-CELL ANTIGEN RECEPTORS) or secreted forms (ANTIBODIES). They are divided by the amino acid sequence of their heavy chains into five classes (IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M) and various subclasses. Globulins, Immune,Immune Globulin,Immune Globulins,Immunoglobulin,Globulin, Immune
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D003176 Complement C3 A glycoprotein that is central in both the classical and the alternative pathway of COMPLEMENT ACTIVATION. C3 can be cleaved into COMPLEMENT C3A and COMPLEMENT C3B, spontaneously at low level or by C3 CONVERTASE at high level. The smaller fragment C3a is an ANAPHYLATOXIN and mediator of local inflammatory process. The larger fragment C3b binds with C3 convertase to form C5 convertase. C3 Complement,C3 Precursor,Complement 3,Complement C3 Precursor,Complement Component 3,Precursor-Complement 3,Pro-C3,Pro-Complement 3,C3 Precursor, Complement,C3, Complement,Complement, C3,Component 3, Complement,Precursor Complement 3,Precursor, C3,Precursor, Complement C3,Pro C3,Pro Complement 3
D003289 Convalescence The period of recovery following an illness. Convalescences
D006501 Hepatic Encephalopathy A syndrome characterized by central nervous system dysfunction in association with LIVER FAILURE, including portal-systemic shunts. Clinical features include lethargy and CONFUSION (frequently progressing to COMA); ASTERIXIS; NYSTAGMUS, PATHOLOGIC; brisk oculovestibular reflexes; decorticate and decerebrate posturing; MUSCLE SPASTICITY; and bilateral extensor plantar reflexes (see REFLEX, BABINSKI). ELECTROENCEPHALOGRAPHY may demonstrate triphasic waves. (From Adams et al., Principles of Neurology, 6th ed, pp1117-20; Plum & Posner, Diagnosis of Stupor and Coma, 3rd ed, p222-5) Encephalopathy, Hepatic,Portosystemic Encephalopathy,Encephalopathy, Hepatocerebral,Encephalopathy, Portal-Systemic,Encephalopathy, Portosystemic,Fulminant Hepatic Failure with Cerebral Edema,Hepatic Coma,Hepatic Stupor,Hepatocerebral Encephalopathy,Portal-Systemic Encephalopathy,Coma, Hepatic,Comas, Hepatic,Encephalopathies, Hepatic,Encephalopathies, Hepatocerebral,Encephalopathies, Portal-Systemic,Encephalopathies, Portosystemic,Encephalopathy, Portal Systemic,Hepatic Comas,Hepatic Encephalopathies,Hepatic Stupors,Hepatocerebral Encephalopathies,Portal Systemic Encephalopathy,Portal-Systemic Encephalopathies,Portosystemic Encephalopathies,Stupor, Hepatic,Stupors, Hepatic
D006509 Hepatitis B INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact. Hepatitis B Virus Infection
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

A G Rakhmanova, and T B Muradnazarova, and N F Amerikantseva, and T P Demidenko, and N V Badosova
[Prognosis factors in acute hepatic insufficiency].
January 2007, Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru,
A G Rakhmanova, and T B Muradnazarova, and N F Amerikantseva, and T P Demidenko, and N V Badosova
[Participation of anticoagulant factors in acute hepatic insufficiency].
December 1979, Revista do Hospital das Clinicas,
A G Rakhmanova, and T B Muradnazarova, and N F Amerikantseva, and T P Demidenko, and N V Badosova
[Study of changes in nonspecific immune factors during acute viral hepatitis].
January 1977, Gastroenterologie clinique et biologique,
A G Rakhmanova, and T B Muradnazarova, and N F Amerikantseva, and T P Demidenko, and N V Badosova
[Late outcome of viral hepatitis associated with acute hepatic insufficiency].
August 1984, Klinicheskaia meditsina,
A G Rakhmanova, and T B Muradnazarova, and N F Amerikantseva, and T P Demidenko, and N V Badosova
[Humoral factors of nonspecific resistance in viral hepatitis in children of different ages].
September 1985, Pediatriia,
A G Rakhmanova, and T B Muradnazarova, and N F Amerikantseva, and T P Demidenko, and N V Badosova
[Acute hepatic insufficiency].
January 1990, Revista chilena de pediatria,
A G Rakhmanova, and T B Muradnazarova, and N F Amerikantseva, and T P Demidenko, and N V Badosova
[Acute hepatic insufficiency].
January 1979, Revista de pediatrie, obstetrica si ginecologie. Pediatria,
A G Rakhmanova, and T B Muradnazarova, and N F Amerikantseva, and T P Demidenko, and N V Badosova
[Hepatic insufficiency and related factors].
August 2006, Revista de gastroenterologia de Mexico,
A G Rakhmanova, and T B Muradnazarova, and N F Amerikantseva, and T P Demidenko, and N V Badosova
Factors Differentiating Acute Hepatitis B from Acute Exacerbation of Chronic Hepatitis B in Prospective-retrospective Cohort.
October 2019, The Journal of the Association of Physicians of India,
A G Rakhmanova, and T B Muradnazarova, and N F Amerikantseva, and T P Demidenko, and N V Badosova
Cerebral vascular resistance in hepatic insufficiency.
August 2001, Journal of gastroenterology and hepatology,
Copied contents to your clipboard!